Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases.

Furthermore, a high percentage of patients (approximately 76%) underwent surgery for prosthesis debridement or replacement together with antimicrobial therapy; they represent the same patients who achieved the primary or secondary outcome. 04***</td></tr></tbody></table> ht 4 Group A: patients receiving a two-dose regimen of dalbavancin; Group B: patients receiving other drugs combination. /></tr></tbody></table> ht 1 Group A: patients receiving a two-dose regimen of dalbavancin; Group B: patients receiving other drugs combination. [Extracted from the article]